Research and specialist diagnostic molecular services
We are a biomedical company with extensive experience in the molecular diagnostic field that allows us to improve the patient’s life quality by putting genetics at their service.
Research and specialist diagnostic molecular services
We are a biomedical company with extensive experience in the molecular diagnostic field that allows us to improve the patient’s life quality by putting genetics at their service.
“In situ” hybridization (FISH)
Highly sensitive technique that allows us to detect chromosomal alterations (number of copies of a gene or a chromosomal rearrangements) in different neoplasms for diagnosis and/or targeted treatment, using probes labeled with a fluorochrome.
Molecular Biology
Molecular biology tools allow us to specifically detect and quantify the genetic material in a biological sample, having a great impact on both the diagnosis of cancer and hereditary and infectious diseases. The appearance of new faster and more precise techniques (arrays or NGS), allow us to perform global genomic analyzes in a short period of time.
News
FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG
In a study published online in The New England Journal of Medicine, Alice T. Shaw
MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR
The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in
OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN
The authors of this phase II trial evaluated the PARP inhibitor olaparib in the
FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH
The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in
FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE
The authors report the 5-year outcomes of this multicenter, double-blind, phase III study of
